Durvalumab combined with concurrent chemoradiotherapy in patients with limited‐stage small cell lung cancer: A prospective, single‐arm, phase 2 clinical trial
Cancer · 2026
DOI: 10.1002/cncr.70351 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer, 2026. Verfasst von Chunyang Song und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Chemoradiotherapy, Antibodies, Monoclonal, Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The current standard treatment for limited‐stage small cell lung cancer (LS‐SCLC) is concurrent chemoradiotherapy (cCRT) plus consolidation immunotherapy, with or without prophylactic cranial irradiation (PCI). However, it remains unknown whether administering immunotherapy concurrently with chemoradiotherapy confers additional benefit. This clinical trial is designed to investigate the efficacy and safety using durvalumab with chemoradiotherapy for LS‐SCLC.
Methods
In this single‐arm phase 2 study, patients with LS‐SCLC received three (1–4) cycles of etoposide, cisplatin, or carboplatin, and durvalumab every 3 weeks, following by thoracic radiotherapy of 60.0 Gy to the gross tumor volume and 54.0 Gy to the planning target volume in 30 once‐daily fractions and chemoimmunotherapy. After cCRT plus durvalumab, patients received durvalumab consolidation therapy every 3 weeks for a minimum of 1 year. PCI was recommended to patients with partial or complete response when chemoradiotherapy completed. Efficacy and adverse events were assessed.
Results
Overall, 51 patients were enrolled from March 1, 2021, to April 30, 2024, with a median follow‐up of 32.0 months. The 1‐, 2‐, and 3‐year progression‐free survival (PFS) rates were 56.9%, 35.9%, and 28.2%, respectively, and the median PFS was 17.0 months. The 1‐, 2‐, and 3‐year overall survival (OS) rates were 88.1%, 68.6%, and 49.6%, respectively, and the median OS was 32.0 months. There were 17 (33.4%) patients with grade 3 or 4 adverse events, 7 of which were immune‑related.
Conclusions
These results suggest that the addition of durvalumab to chemoradiotherapy was well tolerated and showed encouraging efficacy, supporting further investigation in patients with LS‐SCLC eligible for radical chemoradiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
ORCID-Profile: Wenbin Shen
Zitieren
APA
Song, C., Zhao, X., Li, S., Guo, X., Zhang, X., Wang, X., Li, Y., Yan, K., Su, J., Xu, J., Zhu, S., & Shen, W. (2026). Durvalumab combined with concurrent chemoradiotherapy in patients with limited‐stage small cell lung cancer: A prospective, single‐arm, phase 2 clinical trial. Cancer. https://doi.org/10.1002/cncr.70351
Vancouver
Song C, Zhao X, Li S, Guo X, Zhang X, Wang X, et al. Durvalumab combined with concurrent chemoradiotherapy in patients with limited‐stage small cell lung cancer: A prospective, single‐arm, phase 2 clinical trial. Cancer. 2026. doi:10.1002/cncr.70351
BibTeX
@article{Song2026,
author = {Song, Chunyang and Zhao, Xiaohan and Li, Shuguang and Guo, Xuehan and Zhang, Xueyuan and Wang, Xiaobin and Li, Youmei and Yan, Ke and Su, Jingwei and Xu, Jinrui and Zhu, Shuchai and Shen, Wenbin},
title = {Durvalumab combined with concurrent chemoradiotherapy in patients with limited‐stage small cell lung cancer: A prospective, single‐arm, phase 2 clinical trial},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70351}
}
EUVIMED